In transfusion-dependent, lower-risk myelodysplastic syndrome

Unlock the benefits of once-daily oral EXJADE® in treating chronic iron overload

Myelodysplastic Syndromes

EXJADE reduces the burden of iron toxicity

EXJADE clinical studies show reductions in serum ferritin and liver iron concentration. With an established safety profile, EXJADE offers tailored dosing to meet the needs of your patients.

SEE THE RISKS ASSOCIATED WITH IRON TOXICITY

Patients with lower-risk MDS who receive transfusions that extend their survival time face serious consequences from their transfusion therapy.

Learn more

IDENTIFY THE RISK LEVEL OF YOUR MDS PATIENTS

Both the International Prognostic Scoring System and the World Health Organization guidelines can be used to identify the risk level of patients with myelodysplastic syndrome.